» Articles » PMID: 28978689

NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

Overview
Journal J Immunol
Date 2017 Oct 6
PMID 28978689
Citations 723
Authors
Affiliations
Soon will be listed here.
Abstract

Cytotoxic T cells are of central importance in the immune system's response to disease. They recognize defective cells by binding to peptides presented on the cell surface by MHC class I molecules. Peptide binding to MHC molecules is the single most selective step in the Ag-presentation pathway. Therefore, in the quest for T cell epitopes, the prediction of peptide binding to MHC molecules has attracted widespread attention. In the past, predictors of peptide-MHC interactions have primarily been trained on binding affinity data. Recently, an increasing number of MHC-presented peptides identified by mass spectrometry have been reported containing information about peptide-processing steps in the presentation pathway and the length distribution of naturally presented peptides. In this article, we present NetMHCpan-4.0, a method trained on binding affinity and eluted ligand data leveraging the information from both data types. Large-scale benchmarking of the method demonstrates an increase in predictive performance compared with state-of-the-art methods when it comes to identification of naturally processed ligands, cancer neoantigens, and T cell epitopes.

Citing Articles

Manufacturing and Financial Evaluation of Peptide-Based Neoantigen Cancer Vaccines for Triple-Negative Breast Cancer in the United Kingdom: Opportunities and Challenges.

Novakova A, Morris S, Vaiarelli L, Frank S Vaccines (Basel). 2025; 13(2).

PMID: 40006691 PMC: 11860436. DOI: 10.3390/vaccines13020144.


Combined immunoinformatic approaches with computational biochemistry for development of subunit-based vaccine against Lawsonia intracellularis.

Khatooni Z, Broderick G, Anand S, Wilson H PLoS One. 2025; 20(2):e0314254.

PMID: 39992906 PMC: 11849901. DOI: 10.1371/journal.pone.0314254.


Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.

Boll L, Vazquez Montes de Oca S, Camarena M, Castelo R, Bellmunt J, Perera-Bel J Nat Commun. 2025; 16(1):1213.

PMID: 39979258 PMC: 11842772. DOI: 10.1038/s41467-025-56462-0.


Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer.

Raja R, Mangalaparthi K, Madugundu A, Jessen E, Pathangey L, Magtibay P Sci Adv. 2025; 11(8):eads7405.

PMID: 39970218 PMC: 11837991. DOI: 10.1126/sciadv.ads7405.


TumorAgDB1.0: tumor neoantigen database platform.

Shao Y, Gao Y, Wu L, Ge S, Wen P Database (Oxford). 2025; 2025.

PMID: 39968950 PMC: 11836679. DOI: 10.1093/database/baaf010.


References
1.
Andreatta M, Alvarez B, Nielsen M . GibbsCluster: unsupervised clustering and alignment of peptide sequences. Nucleic Acids Res. 2017; 45(W1):W458-W463. PMC: 5570237. DOI: 10.1093/nar/gkx248. View

2.
Pearson H, Daouda T, Granados D, Durette C, Bonneil E, Courcelles M . MHC class I-associated peptides derive from selective regions of the human genome. J Clin Invest. 2016; 126(12):4690-4701. PMC: 5127664. DOI: 10.1172/JCI88590. View

3.
Gubin M, Artyomov M, Mardis E, Schreiber R . Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015; 125(9):3413-21. PMC: 4588307. DOI: 10.1172/JCI80008. View

4.
Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S . NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One. 2007; 2(8):e796. PMC: 1949492. DOI: 10.1371/journal.pone.0000796. View

5.
Bassani-Sternberg M, Gfeller D . Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions. J Immunol. 2016; 197(6):2492-9. DOI: 10.4049/jimmunol.1600808. View